Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 157Lung Neoplasms 73Carcinoma, Hepatocellular 63Small Cell Lung Carcinoma 52Breast Neoplasms 47Squamous Cell Carcinoma of Head and Neck 36Urinary Bladder Neoplasms 30Colorectal Neoplasms 30Neoplasms 29Biliary Tract Neoplasms 29Neoplasm Metastasis 28Cholangiocarcinoma 26Triple Negative Breast Neoplasms 25Pancreatic Neoplasms 25Ovarian Neoplasms 24Head and Neck Neoplasms 19Liver Neoplasms 18Carcinoma, Renal Cell 17Recurrence 16Melanoma 15Stomach Neoplasms 13Prostatic Neoplasms 13Carcinoma 13Endometrial Neoplasms 12Uterine Cervical Neoplasms 11Esophageal Neoplasms 11Carcinoma, Transitional Cell 11Lymphoma, Large B-Cell, Diffuse 10Gallbladder Neoplasms 9Adenocarcinoma Of Esophagus 9

Interventions

Irinotecan 2Injections 2vistusertib 1urelumab 1sapanisertib 1pembrolizumab 1durvalumab 1danvatirsen 1ceralasertib 1cediranib 1atezolizumab 1ZD4054 1Topotecan 1Tiragolumab 1Rosuvastatin Calcium 1Radiotherapy 1Rabeprazole 1Metformin 1HM781-36B 1Furosemide 1Digoxin 1ATP Binding Cassette Transporter, Subfamily B, Member 1 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 13-(1-benzenesulfonyl-2,3-dihydro-1H-indol-5-yl)-N-hydroxyacrylamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Solid Malignancies × durvalumab × Clear all
NCT03394144 2019-06-24

Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies

AstraZeneca

Phase 1 Completed
11 enrolled

Advanced Solid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡